| Literature DB >> 21987742 |
O Reynard1, V Mokhonov, E Mokhonova, J Leung, A Page, M Mateo, O Pyankova, M C Georges-Courbot, H Raoul, A A Khromykh, V E Volchkov.
Abstract
Pre- or postexposure treatments against the filoviral hemorrhagic fevers are currently not available for human use. We evaluated, in a guinea pig model, the immunogenic potential of Kunjin virus (KUN)-derived replicons as a vaccine candidate against Ebola virus (EBOV). Virus like particles (VLPs) containing KUN replicons expressing EBOV wild-type glycoprotein GP, membrane anchor-truncated GP (GP/Ctr), and mutated GP (D637L) with enhanced shedding capacity were generated and assayed for their protective efficacy. Immunization with KUN VLPs expressing full-length wild-type and D637L-mutated GPs but not membrane anchor-truncated GP induced dose-dependent protection against a challenge of a lethal dose of recombinant guinea pig-adapted EBOV. The surviving animals showed complete clearance of the virus. Our results demonstrate the potential for KUN replicon vectors as vaccine candidates against EBOV infection.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21987742 PMCID： PMC3189994 DOI： 10.1093/infdis/jir347
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226